Transgene rises on encouraging signs from cancer treatment trial

Transgene SA

27/06/2022 08:51

** Shares in Transgene  TRNG.PA  rise 6.7% after the
France-based biopharma company announced "positive progress" for
its cancer-treating BT-001 oncolytic virus 
    ** The company says the phase I/IIA trial evaluating BT-001
in patients with solid tumours showed positive progress and
safety data, with first signs of anti-tumour activity in
hard-to-treat population  urn:newsml:reuters.com:*:nFWN2YC0VP
    ** Transgene plans to start Phase I part B in H2
    ** Kempen Research says it is "encouraged by evidence of
localized production of anti-CTLA-4 within the tumor
microenvironment, which could address the toxicity issues seen
with currently available anti-CTLA-4 treatment"
    ** CTLA-4 is a protein receptor functioning as an immune
checkpoint which downregulates the immune response
    ** The stock has dropped by 15% YTD

 (Reporting by Olivier Sorgho)
 ((Olivier.sorgho@thomsonreuters.com))